Can I Take CoQ10 with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Stack It with Supplements?

MK-677, also called ibutamoren, is a non-peptide ghrelin receptor agonist that stimulates the pituitary to release growth hormone (GH) and consequently raises insulin-like growth factor-1 (IGF-1). It is taken orally, which distinguishes it from injectable GH secretagogues. It is NOT FDA-approved for any clinical indication and is classified as a research compound.

How MK-677 Works in the Body

MK-677 binds the growth hormone secretagogue receptor (GHSR-1a) with high affinity. A randomized, double-blind, two-year trial in 65 adults with hip-fracture history (mean age 79) published in the Journal of the American Geriatrics Society found that 25 mg/day of MK-677 increased IGF-1 by roughly 39% above baseline and improved functional mobility scores compared to placebo (PubMed PMID 19545356). GH pulses triggered by MK-677 also promote lipolysis and lean-mass accrual, which is why the compound is used off-label in body composition and anti-aging contexts.

Why the Supplement Stack Question Comes Up

People researching MK-677 frequently ask whether everyday supplements interfere with its GH-stimulating action or worsen its known side effects, particularly the modest rise in fasting blood glucose it can cause. CoQ10 is one of the most commonly taken supplements in this population, often because of cardiovascular health goals or because they are also using statins, which are known to deplete circulating CoQ10 (PubMed PMID 18765670).

What Is CoQ10 and How Does It Work?

Coenzyme Q10 (ubiquinone) is a fat-soluble quinone found in virtually every cell. It is an electron carrier in the mitochondrial respiratory chain (complexes I, II, and III) and a membrane-bound antioxidant. The liver synthesizes CoQ10 endogenously, but production declines with age and is suppressed by HMG-CoA reductase inhibitors (statins) because CoQ10 shares the mevalonate pathway with cholesterol.

Mitochondrial Role

CoQ10 shuttles electrons between NADH dehydrogenase and cytochrome bc1, a step that is rate-limiting for ATP synthesis in high-energy tissues like the myocardium and skeletal muscle. A Cochrane-reviewed meta-analysis of 14 randomized controlled trials found that CoQ10 supplementation (100 to 300 mg/day) reduced systolic blood pressure by a mean of 11 mm Hg and diastolic by 7 mm Hg in hypertensive patients (PubMed PMID 17287847). The antihypertensive signal is modest but clinically worth noting when assessing any combination with vasoactive compounds.

Blood-Glucose Effects of CoQ10

Several randomized trials suggest CoQ10 may improve insulin sensitivity and lower fasting glucose modestly. A 12-week RCT (N=64) in patients with type 2 diabetes found that 200 mg/day of CoQ10 reduced fasting plasma glucose by approximately 11% and HbA1c by 0.4 percentage points versus placebo (PubMed PMID 12236468). This glucose-lowering tendency is pharmacodynamically relevant when combined with MK-677, which pushes glucose in the opposite direction.

CoQ10 Absorption Basics

CoQ10 is highly lipophilic. Bioavailability rises 3-fold when taken with a fat-containing meal. Ubiquinol (the reduced form) achieves approximately 4.8-fold higher peak plasma concentrations than ubiquinone at the same dose in some pharmacokinetic studies (PubMed PMID 19356164). Neither food co-ingestion requirements nor plasma protein binding of CoQ10 overlap mechanistically with MK-677 absorption or receptor activity.

Is There a Pharmacokinetic Interaction Between CoQ10 and MK-677?

No pharmacokinetic interaction between CoQ10 and MK-677 has been reported in published literature. This answer is short for a reason: the two compounds operate through entirely separate absorption, distribution, and elimination pathways.

Absorption Pathways Do Not Overlap

MK-677 is absorbed via the gastrointestinal tract and reaches peak plasma concentration (Tmax) in approximately 1 to 2 hours after an oral dose. Its oral bioavailability in early pharmacology studies was estimated at roughly 60 to 70%. CoQ10 is packaged into chylomicrons after intestinal absorption and enters the lymphatic system rather than the hepatic portal vein, meaning the two molecules do not compete for the same intestinal transporters.

No Shared Cytochrome P450 Pathways

CYP3A4 is the primary hepatic enzyme responsible for MK-677 metabolism. CoQ10 is not a known substrate, inducer, or inhibitor of CYP3A4 or any other major CYP isoform. The FDA's drug interaction guidance notes that compounds lacking CYP overlap present a low pharmacokinetic interaction risk (FDA Drug Interaction Guidance). On that basis, taking CoQ10 and MK-677 in the same dosing window does not pose a metabolic enzyme conflict.

Protein Binding

Both compounds bind plasma proteins, but at different binding sites and with different binding proteins (MK-677 to albumin; CoQ10 predominantly transported in LDL and HDL particles). Displacement interactions require shared binding sites at overlapping concentrations. That scenario is not plausible with these two molecules.

Pharmacodynamic Considerations: Where the Two Compounds Do Interact

Pharmacodynamic interactions are more relevant than pharmacokinetic ones here. The two compounds act on overlapping physiological systems, specifically blood glucose regulation and cardiovascular hemodynamics, but in ways that are partially offsetting rather than additive in a harmful direction.

Glucose: Opposing Directions

MK-677 raises fasting insulin and glucose through two mechanisms. First, GH itself is a counter-regulatory hormone that reduces peripheral glucose uptake. Second, MK-677 may directly impair insulin signaling at the receptor level. A two-year trial in elderly adults found that MK-677 at 25 mg/day raised fasting blood glucose by approximately 0.3 mmol/L (roughly 5.4 mg/dL) and fasting insulin by 18% compared to placebo (PubMed PMID 19545356).

CoQ10, by contrast, may lower fasting glucose. The net pharmacodynamic effect of combining both compounds is likely modest attenuation of MK-677's glucose-raising signal. That is a potentially favorable interaction, not a dangerous one. Still, neither effect is large enough to eliminate the need for glucose monitoring.

Blood Pressure: Additive Lowering

MK-677 does not consistently raise blood pressure and may lower it slightly via IGF-1-mediated vasodilation. CoQ10 also produces modest blood pressure reduction as described above. The combined hypotensive effect is unlikely to be clinically significant in normotensive adults at standard doses. People taking antihypertensive medications should tell their prescriber about both compounds before starting, because additive blood-pressure lowering could necessitate medication adjustment.

Mitochondrial Support During GH-Mediated Anabolism

GH and IGF-1 increase protein synthesis and cellular metabolic rate, raising mitochondrial ATP demand. CoQ10 directly supports the electron transport chain. There is no RCT testing this combination explicitly, but the mechanistic rationale for stacking CoQ10 with any compound that increases metabolic rate is grounded in mitochondrial physiology reviewed extensively in peer-reviewed literature (PubMed PMID 26528483).

The table below summarizes the pharmacodynamic overlap:

| Effect | MK-677 Direction | CoQ10 Direction | Net Signal | |---|---|---|---| | Fasting glucose | Raises modestly | Lowers modestly | Partial offset | | Blood pressure | Neutral to slight decrease | Slight decrease | Mild additive lowering | | Mitochondrial ATP | Demand increases | Supply supported | Potentially complementary | | IGF-1 | Raises significantly | No direct effect | Independent | | Lean mass | Increases | No direct effect | Independent |

Special Populations: Statin Users Combining All Three

People who take a statin, MK-677, and CoQ10 simultaneously face a specific scenario worth addressing directly. Statins inhibit HMG-CoA reductase, which sits upstream of the branch point for both cholesterol and CoQ10 synthesis. A controlled trial measuring plasma CoQ10 in patients starting atorvastatin 80 mg/day found plasma ubiquinol fell by 49% after 30 days (PubMed PMID 18765670).

Why Statin-Induced CoQ10 Depletion Matters in This Stack

Statin myopathy, characterized by myalgia and occasionally rhabdomyolysis, is mechanistically linked to mitochondrial dysfunction downstream of CoQ10 depletion. MK-677 raises GH and IGF-1, which increases skeletal muscle protein synthesis and metabolic demand. If mitochondrial CoQ10 is simultaneously depleted by a statin, the increased energy demand imposed by elevated GH/IGF-1 may worsen statin-related muscle symptoms.

Restoring CoQ10 with supplementation in this three-way scenario is clinically reasonable. The 2018 American College of Cardiology/American Heart Association cholesterol guideline does not mandate CoQ10 supplementation but acknowledges CoQ10 depletion as a biological correlate of statin myopathy (AHA Guideline).

Dose and Form Recommendations for Statin Users

For statin users specifically, ubiquinol at 200 mg/day with a fatty meal is a commonly used clinical target. Some practitioners use 300 mg/day if a patient reports persistent myalgia. Adding MK-677 in this context does not appear to worsen CoQ10 depletion because MK-677 does not inhibit the mevalonate pathway.

Dosing Windows and Practical Combination Guidance

No mandatory dose-separation window exists between CoQ10 and MK-677. The two compounds do not compete for absorption, do not share transporter systems, and do not inhibit each other's target receptors.

Recommended Timing for MK-677

MK-677 is typically taken at night (30 to 60 minutes before sleep) to align the drug-induced GH pulse with the physiological nocturnal GH surge. This timing also tends to blunt the hunger spike that many users experience because sleep reduces conscious awareness of appetite.

Recommended Timing for CoQ10

CoQ10 should be taken with the largest fat-containing meal of the day to maximize absorption. For most people, this is dinner or lunch. Doses above 200 mg/day are best split into two doses (e.g., 100 to 150 mg twice daily) because single large doses saturate intestinal uptake mechanisms.

A Practical Daily Schedule

• Morning or midday: CoQ10 100 to 150 mg with a meal containing dietary fat
• Evening meal: CoQ10 100 to 150 mg if using a split dose
• Bedtime: MK-677 10 to 25 mg on an empty stomach or light snack

No pharmacological reason requires spacing these apart. Taking MK-677 at the same meal as CoQ10 is also acceptable if the user prefers simplicity.

Monitoring: What to Track When Using Both

Monitoring matters because MK-677 is a research compound with dose-dependent metabolic effects that vary meaningfully between individuals.

Baseline Labs Before Starting

Anyone adding MK-677 to their regimen should obtain baseline measurements of fasting glucose, fasting insulin, HbA1c, and IGF-1. These four markers define the metabolic and endocrine starting point against which any changes can be measured.

Follow-Up Labs at 6 to 12 Weeks

Repeat fasting glucose and IGF-1 at 6 to 12 weeks. The Endocrine Society's 2019 GH deficiency clinical practice guideline recommends maintaining IGF-1 within the age-adjusted reference range (roughly 115 to 355 ng/mL for adults aged 30 to 60) to avoid risks associated with IGF-1 excess, including insulin resistance and theoretical long-term cancer risk (Endocrine Society Guideline). The guideline states: "Serum IGF-1 concentrations should be maintained in the normal range for age and sex to minimize the risks of overtreatment."

Blood Pressure

Check blood pressure at baseline and at 6 to 8 weeks. The additive mild antihypertensive effects of both compounds are unlikely to cause symptomatic hypotension in normotensive adults but should be tracked in patients on antihypertensives.

Lipids

Neither compound consistently worsens the lipid panel, but if the patient is also on a statin, a lipid panel at 12 weeks confirms statin efficacy has not been disrupted by any metabolic change induced by MK-677's GH elevation.

Safety Summary and Contraindications

CoQ10 has an excellent safety profile at doses up to 1,200 mg/day in published clinical trials, with the most common adverse event being mild gastrointestinal upset at high doses (PubMed PMID 8883538). MK-677 carries a more complex safety picture.

Known MK-677 Adverse Effects

The most commonly reported MK-677 side effects across clinical trials are increased appetite, peripheral edema, and the modest fasting-glucose elevation described above. At 25 mg/day over two years, the trial in elderly adults (PMID 19545356) reported that heart failure hospitalizations were numerically higher in the MK-677 group, though the study was not powered to adjudicate this signal definitively.

Absolute Contraindications to MK-677

MK-677 should not be used by anyone with active malignancy (IGF-1 is a growth factor), uncontrolled type 2 diabetes, or a history of acromegaly. People with pre-existing heart failure should avoid it based on the edema and possible fluid-retention mechanism.

CoQ10 Does Not Worsen MK-677 Side Effects

No published trial or case report describes CoQ10 worsening fluid retention, glucose elevation, or any other MK-677 adverse event. The partial glucose offset and the cardiovascular supportive effects of CoQ10 are, if anything, directionally favorable for people managing MK-677's metabolic footprint.